Research programme: micacocidin analogues - ShionogiAlternative Names: Micacocidin analogues research programme - Shionogi
Latest Information Update: 09 Jul 2002
At a glance
- Originator Shionogi
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoplasma infections
Most Recent Events
- 09 Jul 2002 Discontinued - Preclinical for Mycoplasma infections in Japan (unspecified route)
- 17 Oct 2001 Preclinical development for Mycoplasma infections in Japan (Unknown route)